MoonLake Immunotherapeutics | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -47.5M
Net Income -40.6M
EPS (Diluted) $-0.63

Balance Sheet Metrics

Total Assets 511.3M
Total Liabilities 98.7M
Shareholders Equity 412.6M
Debt to Equity 0.24

Cash Flow Metrics

Operating Cash Flow -39.9M
Free Cash Flow -38.2M

Revenue & Profitability Trend

MoonLake Income Statement From 2022 to 2024

Metric202420232022
Revenue i000
Cost of Goods Sold i---
Gross Profit i---
Gross Margin % i0.0%0.0%0.0%
Operating Expenses
Research & Development i112.8M31.8M42.0M
Selling, General & Administrative i30.3M22.3M23.0M
Other Operating Expenses i---
Total Operating Expenses i143.1M54.1M65.1M
Operating Income i-143.1M-54.1M-65.1M
Operating Margin % i0.0%0.0%0.0%
Non-Operating Items
Interest Income i---
Interest Expense i---
Other Non-Operating Income22.1M10.1M591.7K
Pre-tax Income i-121.0M-44.0M-64.5M
Income Tax i282.2K94.4K36.4K
Effective Tax Rate % i0.0%0.0%0.0%
Net Income i-121.2M-44.1M-64.5M
Net Margin % i0.0%0.0%0.0%
Key Metrics
EBITDA i-141.7M-54.1M-65.0M
EPS (Basic) i$-1.89$-0.73$-1.70
EPS (Diluted) i$-1.89$-0.73$-1.70
Basic Shares Outstanding i628702374912253429361353
Diluted Shares Outstanding i628702374912253429361353

Income Statement Trend

MoonLake Balance Sheet From 2021 to 2024

Metric2024202320222021
Assets
Current Assets
Cash & Equivalents i180.4M451.2M39.5M8.0M
Short-term Investments i267.6M59.8M32.6M0
Accounts Receivable i----
Inventory i----
Other Current Assets----
Total Current Assets i474.3M514.2M76.5M9.6M
Non-Current Assets
Property, Plant & Equipment i722.2K3.9M332.0K45.7K
Goodwill i----
Intangible Assets i----
Long-term Investments----
Other Non-Current Assets----
Total Non-Current Assets i3.6M12.4M332.0K45.7K
Total Assets i477.9M526.5M76.8M9.7M
Liabilities
Current Liabilities
Accounts Payable i8.7M553.5K66.0K1.2M
Short-term Debt i1.4M1.3M153.6K15.0M
Current Portion of Long-term Debt----
Other Current Liabilities----
Total Current Liabilities i22.5M10.0M7.7M21.1M
Non-Current Liabilities
Long-term Debt i1.5M2.5M129.0K0
Deferred Tax Liabilities i----
Other Non-Current Liabilities----
Total Non-Current Liabilities i2.1M3.1M411.2K239.9K
Total Liabilities i24.5M13.0M8.1M21.3M
Equity
Common Stock i6.4K6.3K5.3K38.5K
Retained Earnings i-235.6M-116.7M-80.7M-53.6M
Treasury Stock i--06.2K
Other Equity----
Total Shareholders Equity i453.4M513.5M68.8M-11.6M
Key Metrics
Total Debt i2.8M3.8M282.6K15.0M
Working Capital i451.8M504.2M68.8M-11.5M

Balance Sheet Composition

MoonLake Cash Flow Statement From 2022 to 2024

Metric202420232022
Operating Activities
Net Income i-121.2M-44.1M-64.5M
Depreciation & Amortization i1.4M13.2K12.4K
Stock-Based Compensation i7.3M7.1M9.7M
Working Capital Changes i-3.2M-1.2M-220.8K
Operating Cash Flow i-116.0M-37.7M-54.8M
Investing Activities
Capital Expenditures i-519.5K-284.6K-16.0K
Acquisitions i---
Investment Purchases i-350.3M-175.7M-42.2M
Investment Sales i145.2M150.8M9.9M
Investing Cash Flow i-205.6M-25.2M-32.3M
Financing Activities
Share Repurchases i-50-0
Dividends Paid i---
Debt Issuance i---
Debt Repayment i00-15.0M
Financing Cash Flow i51.1M479.7M119.7M
Free Cash Flow i-117.1M-43.1M-55.9M
Net Change in Cash i-270.5M416.8M32.5M

Cash Flow Trend

MoonLake Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -4.46
Forward P/E -3.36
Price to Book 1.51
PEG Ratio -0.04

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -40.34%
Return on Assets -24.99%

Financial Health

Current Ratio 16.65
Debt to Equity 21.17
Beta 1.10

Per Share Data

EPS (TTM) $-2.79
Book Value per Share $5.57
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mltx535.3M-4.461.51-40.34%0.00%21.17
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Vera Therapeutics 2.0B-10.964.11-54.84%0.00%16.56
Dyne Therapeutics 2.0B-3.882.61-61.32%0.00%21.19
Liquidia 1.9B-13.51126.72-389.13%58.00%1,319.26

Financial data is updated regularly. All figures are in the company's reporting currency.